BRAF and cancer: Initially described in 2002, BRAF mutations lead to constitutive activation of the kinase BRAF and, consequently, of the RAF-MEK-ERK signaling cascade, promoting cell proliferation and survival, while inhibiting apoptosis, ultimately driving cancer growth [13, 14].